Capital Research Global Investors Buys 574,173 Shares of CVS Health Corporation $CVS

Capital Research Global Investors increased its stake in CVS Health Corporation (NYSE:CVS) by 5.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,043,423 shares of the pharmacy operator’s stock after buying an additional 574,173 shares during the quarter. Capital Research Global Investors owned about 0.95% of CVS Health worth $955,766,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd increased its stake in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares during the period. Ares Financial Consulting LLC purchased a new stake in CVS Health in the fourth quarter worth $29,000. Dogwood Wealth Management LLC increased its stake in CVS Health by 93.7% in the fourth quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock worth $29,000 after purchasing an additional 179 shares during the period. GoalVest Advisory LLC purchased a new stake in CVS Health in the fourth quarter worth $32,000. Finally, MidAtlantic Capital Management Inc. purchased a new stake in CVS Health in the fourth quarter worth $35,000. 80.66% of the stock is currently owned by institutional investors.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health was upgraded to a Zacks Rank #2 (Buy), reflecting improved earnings optimism and adding to the bullish tone around the stock. Article Title
• Positive Sentiment: Broker sentiment remains constructive on CVS Health, with recent coverage pointing to favorable views from Wall Street analysts and broader confidence in the company’s outlook. Article Title
• Positive Sentiment: The managed-care group rallied after analysts cited softer medical cost and utilization trends across the sector, which can support margins and spill over positively to CVS Health. Article Title
• Neutral Sentiment: CVS Health highlighted community and affordable-housing projects in New Jersey and Massachusetts, underscoring its corporate social responsibility efforts, but these announcements are unlikely to move the stock materially. Article Title
• Neutral Sentiment: Media coverage noted CVS Health is up about 8.5% since its last earnings report and asked whether the rally can continue, mainly reflecting investor attention on post-earnings momentum rather than a new catalyst. Article Title
• Neutral Sentiment: CVS CEO comments on AI, “super apps,” and primary care suggest longer-term strategy focus, but there was no immediate financial update in the coverage. Article Title
• Neutral Sentiment: Additional community partnership news, including a job training lab in Lincoln Heights, is supportive of the brand but not a direct earnings driver. Article Title

Insider Activity

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares in the company, valued at $586,842,501.45. This trade represents a 24.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,441,551 shares of company stock worth $323,703,977 in the last quarter. 0.85% of the stock is owned by insiders.

CVS Health Stock Performance

Shares of CVS Health stock opened at $96.11 on Friday. The firm has a market cap of $122.62 billion, a P/E ratio of 42.34, a P/E/G ratio of 0.94 and a beta of 0.62. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $98.43. The stock’s fifty day moving average price is $84.13 and its 200-day moving average price is $80.03.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities research analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date was Thursday, April 23rd. CVS Health’s payout ratio is 117.18%.

Analyst Upgrades and Downgrades

CVS has been the topic of a number of recent analyst reports. Sanford C. Bernstein increased their target price on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 12th. UBS Group increased their target price on CVS Health from $97.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Truist Financial increased their target price on CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. The Goldman Sachs Group increased their target price on CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Finally, HSBC increased their target price on CVS Health from $83.00 to $85.00 and gave the stock a “hold” rating in a research note on Tuesday, May 5th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.88.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.